2015 American Transplant Congress
Treatment of Hepatitis C Virus in Kidney Transplant Recipients With Direct Acting Anti-Viral Agents: Early Results in 12 Cases
Background: Recently approved direct acting antiviral agents (DAA) for treatment of HCV are interferon sparing allowing an attractive treatment option for kidney transplant recipient with…2015 American Transplant Congress
Safety and Efficacy of Pegylated Interferon and Ribavirin for Chronic Hepatitis C Following Renal Transplantation
Objective We sought to investigate the safety and efficacy of pegylated Interferon (PEG-IFN) and ribavirin for chronic hepatitis C (HCV) following renal transplantation.Methods Ten adult…2015 American Transplant Congress
The Benefit of Hepatitis C Donor Kidney Transplantation Is Limited to Hepatitis C Positive Patients Over 50 Years of Age
Division of Nephrology, University of British Columbia, Vancouver, BC, Canada.
The purpose of this analysis was to provide information regarding the use and survival benefit of kidney transplantation from a hepatitis C positive deceased donor…2015 American Transplant Congress
Long-term Patient and Graft Survival After Kidney Transplantation in Recipients With Hepatitis C Virus Infection
Division of Gastroenterology and Hepatology, Stanford University, Stanford.
Background: The prevalence of hepatitis C virus (HCV) infection among kidney transplant (KTx) recipients is higher than that in the general population. With the advent…2015 American Transplant Congress
Combined Hepatitic/Cholangiopathic Lesion in HIV-HCV Co-Infected Liver Transplant Recipients Associated With Graft Loss
Background: Co-infection with HIV and viral hepatitis results in poorer outcomes following liver transplantation. In this population, complex immune status, extensive drug regimens, and comorbid…2015 American Transplant Congress
Interferon-Free Sofosvir/Ribavirin Treatment Achieves Excellent Sustained Viral Response in Post Liver Transplant HCV Recipients
Purpose: HCV is the leading cause of end-stage liver disease, universally recurring in the post-transplant setting. Studies have shown disappointing results after first generation protease…2015 American Transplant Congress
HCV Treatment in Liver Transplantation: Changes in Center Attitudes and Practices in the DAA Era
Surgery, Johns Hopkins University, Baltimore, MD.
Chronic hepatitis C virus infection (HCV) is the leading indication for liver transplantation (LT) in the US. Safe and effective directly acting antivirals (DAAs) are…2015 American Transplant Congress
Efficacy of Sofosbuvir Based Therapy for Recurrent Hepatitis C After Liver Transplantation
Purpose: Evaluate outcomes of sofosbuvir-based hepatitis C therapy in liver transplant patients in a single center clinical setting, including interferon-free regimens.Methods: All patients with history…
- « Previous Page
- 1
- …
- 26
- 27
- 28